GlobalData on MSN22 小时
Alkermes begins Phase II trial of drug candidate for idiopathic hypersomniaAlkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 in adults with idiopathic ...
Zacks Investment Research on MSN23 小时
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680Alkermes plc ALKS announced that it has initiated the phase II Vibrance-3 study, evaluating the novel, investigational and ...
idiopathic hypersomnia or multiple sclerosis. Serum from patients with narcolepsy showed higher levels of TRIB2 autoantibodies than all the other patient groups tested. These autoantibody titers ...
Alkermes (ALKS) announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to ...
Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic ...
narcolepsy type 2, and idiopathic hypersomnia, at the American Academy of Neurology 2025 Annual Meeting in San Diego from April 5-9, 2025. This investigational drug is also under evaluation in a ...
Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈